Early Phase Development

Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk

September 14, 2022

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

Animal Models Are Seeing Upgrades to Tackle Complex Molecule Testing

August 10, 2022

Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.

Precision BioSciences Releases Data on CAR T Therapy Candidates

June 13, 2022

Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.

The Essential Ingredient in any Sponsor-CRO Partnership: Trust

May 16, 2022

To build trust and ensure a high-quality product, companies must be sure their contracts are firm and their lines of communication even firmer.

The Next Step For COVID-19 Vaccines

March 09, 2022

New technologies are treatments are emerging to tackle COVID-19 and its assortment of new variants.

What’s Next for COVID-19 Vaccines and Variants?

January 02, 2022

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants.

Sanofi to Acquire Origimm Biotechnology for Vaccine-based Acne Treatment

December 09, 2021

Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.

Secarna Pharmaceuticals and Achilles Therapeutics Partner on T Cell Therapy Development

November 19, 2021

Secarna Pharmaceuticals and Achilles Therapeutics have entered into an agreement to optimize the development of T cell therapies in Achilles’ pipeline.

Biopharma Industry is Seeing Merit in Early Preclinical Strategies

November 01, 2021

The biopharma industry is seeing more merit in strategizing clinical and commercial drug development as early as the preclinical phase.

MilliporeSigma Licenses CRISPR-Cas9 Technology to Cellecta

October 11, 2021

MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, signed an agreement with Cellecta to license its genome-editing tool.